Cytokinetics Inc financial data

Symbol
CYTK on Nasdaq
Industry
Pharmaceutical Preparations
Location
350 Oyster Point Boulevard, ., South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 797 % +4.18%
Debt-to-equity -1.28K % -285%
Return On Equity 540 % +256%
Return On Assets -45.6 % +29.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 118M shares +15%
Common Stock, Shares, Outstanding 118M shares +16.3%
Entity Public Float 5.6B USD +180%
Common Stock, Value, Issued 118K USD +15.7%
Weighted Average Number of Shares Outstanding, Basic 112K shares +16%
Weighted Average Number of Shares Outstanding, Diluted 112K shares +16%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 18.5M USD +145%
Research and Development Expense 339M USD +2.81%
General and Administrative Expense 215M USD +24%
Operating Income (Loss) -536M USD -8.07%
Nonoperating Income (Expense) 51.5M USD +86.5%
Net Income (Loss) Attributable to Parent -590M USD -12%
Earnings Per Share, Basic -5.26 USD/shares +3.49%
Earnings Per Share, Diluted -5.26 USD/shares +3.49%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 94.9M USD -16.1%
Cash, Cash Equivalents, and Short-term Investments 1.22B USD +86.3%
Accounts Receivable, after Allowance for Credit Loss, Current 16.7M USD +1198%
Assets, Current 1.11B USD +76.4%
Property, Plant and Equipment, Net 65.8M USD -4.27%
Operating Lease, Right-of-Use Asset 75.2M USD -4.85%
Other Assets, Noncurrent 7.71M USD -3.64%
Assets 1.4B USD +70%
Accounts Payable, Current 20.4M USD -5.29%
Employee-related Liabilities, Current 35.1M USD +20.1%
Accrued Liabilities, Current 55.3M USD +29.7%
Liabilities, Current 180M USD +75%
Operating Lease, Liability, Noncurrent 113M USD -6.51%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 1.54B USD +27%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.4M USD
Retained Earnings (Accumulated Deficit) -2.7B USD -27.9%
Stockholders' Equity Attributable to Parent -135M USD +65%
Liabilities and Equity 1.4B USD +70%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -130M USD -5.91%
Net Cash Provided by (Used in) Financing Activities 104M USD
Net Cash Provided by (Used in) Investing Activities 32.6M USD -80.3%
Common Stock, Shares Authorized 163M shares 0%
Common Stock, Shares, Issued 118M shares +16.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.95M USD -80.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 95.2M USD -16%
Interest Paid, Excluding Capitalized Interest, Operating Activities 10.2M USD +25415%
Deferred Tax Assets, Valuation Allowance 713M USD +24.5%
Deferred Tax Assets, Gross 735M USD +23.2%
Operating Lease, Liability 132M USD -4.89%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -587M USD -12.3%
Lessee, Operating Lease, Liability, to be Paid 191M USD -8.94%
Property, Plant and Equipment, Gross 103M USD +6.07%
Operating Lease, Liability, Current 19M USD +6.08%
Lessee, Operating Lease, Liability, to be Paid, Year Two 20.2M USD +3.15%
Lessee, Operating Lease, Liability, to be Paid, Year One 19.6M USD +4.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 59.4M USD -16.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 20.5M USD +1.66%
Deferred Tax Assets, Operating Loss Carryforwards 283M USD +22%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 31M USD +22.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 20.7M USD +1.09%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.33M USD +26.1%
Share-based Payment Arrangement, Expense 97.8M USD +35.8%
Interest Expense 37.7M USD +33.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%